Clinical features of adults with seven-valent-conjugated-vaccine-serotype pneumococcal pneumonia

Chamira Rodrigo*, Thomas Bewick, Carmen Sheppard, Sonia Greenwood, Caroline Trotter, Mary Slack, Robert George, Wei Shen Lim

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)

Abstract

Background: Despite the reduction in adult invasive pneumococcal disease through 'herd protection' consequent to the introduction of childhood pneumococcal conjugate vaccination (PCV), a significant proportion of adults continue to develop pneumococcal pneumonia caused by one of the seven serotypes included in the seven-valent conjugated pneumococcal vaccine (PCV7). The clinical features and outcomes of these adults have not been previously reported. Methods: Adults recruited over a three year period to a large prospective cohort study of community acquired pneumonia (CAP) were investigated for pneumococcal serotypes using a validated multiplex immunoassay (Bio-plex). The baseline characteristics and outcomes of adults with PCV7-serotype CAP in comparison to those with non-PCV7-serotype CAP were established. Results: Pneumococcal aetiology was identified in 415 of 1166 (35.6%) individuals, and a serotype determined in 287 (69.2%). Following exclusion of three individuals with both a PCV7 and non-PCV7 serotype, 77 of the remaining 284 (27.1%) adults had CAP due to PCV7 serotypes. Adults with PCV7-serotype CAP were older (median years (inter-quartile range) 73.3 (60.8-84.4) versus 65.0 (46.1-78.0); p= 0.001) and were more likely to have a World Health Organisation performance status ≥1 (odds ratio (OR) 2.05, 95% confidence interval (CI) 1.21-3.50).The presence of stroke (adjusted OR 2.84, 95% CI 1.36-5.95) and dementia (adjusted OR 3.55, 95% CI 1.26-9.94) as underlying co-morbid illnesses were independently associated with PCV7-serotype CAP; 30-day mortality was significantly greater in adults with PCV7-serotype CAP (adjusted OR 4.38, 95% CI 1.85-10.34). Conclusion: A significant proportion of adults continue to develop PCV7-serotype CAP in the era of childhood pneumococcal conjugate vaccination. These adults are more likely to have stroke and dementia as underlying co-morbid illnesses, and have a higher 30-day mortality. A combination of pneumococcal transmission factors, host factors and pneumococcal serotype specific characteristics are likely to explain these findings.

Original languageEnglish
Pages (from-to)1460-1465
Number of pages6
JournalVaccine
Volume32
Issue number13
DOIs
Publication statusPublished - 14 Mar 2014

Bibliographical note

Funding Information:
All authors declare to have no conflict of interest specific to the subject. CR has received salaries part funded by an unrestricted grant from Pfizer and an NIHR grant. TB and SG have received salaries derived from an unrestricted grant from Pfizer. WSL has received funding from the NIHR and an unrestricted research grant from Pfizer. MS has served on advisory boards for Pfizer, GlaxoSmithKline (GSK) and Merck, and her department has received research grants from Pfizer and GSK, and has received payment for lectures at symposia in overseas conferences organised by GSK and Pfizer. CT has no competing interests to declare. CS has received funding to attend international conferences from Pfizer and Luminex. RG has received grants from Pfizer and GSK, and has received travel and accommodation expenses for overseas conferences from Pfizer and GSK.

Keywords

  • Pneumococcal
  • Pneumonia
  • Serotype
  • Vaccine

Fingerprint

Dive into the research topics of 'Clinical features of adults with seven-valent-conjugated-vaccine-serotype pneumococcal pneumonia'. Together they form a unique fingerprint.

Cite this